T1	Participants 39 118	previously treated patients with refractory advanced non-small-cell lung cancer
T2	Participants 295 445	the effect on survival of gefitinib as second-line or third-line treatment for patients with locally advanced or metastatic non-small-cell lung cancer
T3	Participants 455 658	1692 patients who were refractory to or intolerant of their latest chemotherapy regimen were randomly assigned in a ratio of two to one either gefitinib (250 mg/day) or placebo, plus best supportive care
T4	Participants 672 762	endpoint was survival in the overall population of patients and those with adenocarcinoma.
T5	Participants 942 996	1129 patients were assigned gefitinib and 563 placebo.
